Diabetes & Metabolism Journal

Review

Guideline/Fact Sheet
Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Mellitus: A Review and Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association: Jaehyun Bae, Eugene Han, Hye Won Lee, Cheol-Young Park, Choon Hee Chung, Dae Ho Lee, Eun-Hee Cho, Eun-Jung Rhee, Ji Hee Yu, Ji Hyun Park, Ji-Cheol Bae, Jung Hwan Park, Kyung Mook Choi, Kyung-Soo Kim, Mi Hae Seo, Minyoung Lee, Nan-Hee Kim, So Hun Kim, Won-Young Lee, Woo Je Lee, Yeon-Kyung Choi, Yong-ho Lee, You-Cheol Hwang, Young Sang Lyu, Byung-Wan Lee, Bong-Soo Cha, on Behalf of the Fatty Liver Research Group of the Korean Diabetes Association; Diabetes Metab J. 2024;48(6):1015-1028. Published online November 1, 2024; DOI: https://doi.org/10.4093/dmj.2024.0541

17,444 View
564 Download
18 Web of Science
19 Crossref

Since the role of the liver in metabolic dysfunction, including type 2 diabetes mellitus, was demonstrated, studies on non-alcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated fatty liver disease (MAFLD) have shown associations between fatty liver disease and other metabolic diseases. Unlike the exclusionary diagnostic criteria of NAFLD, MAFLD diagnosis is based on the presence of metabolic dysregulation in fatty liver disease. Renaming NAFLD as MAFLD also introduced simpler diagnostic criteria. In 2023, a new nomenclature, steatotic liver disease (SLD), was proposed. Similar to MAFLD, SLD diagnosis is based on the presence of hepatic steatosis with at least one cardiometabolic dysfunction. SLD is categorized into metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol-related/-associated liver disease, alcoholrelated liver disease, specific etiology SLD, and cryptogenic SLD. The term MASLD has been adopted by a number of leading national and international societies due to its concise diagnostic criteria, exclusion of other concomitant liver diseases, and lack of stigmatizing terms. This article reviews the diagnostic criteria, clinical relevance, and differences among NAFLD, MAFLD, and MASLD from a diabetologist’s perspective and provides a rationale for adopting SLD/MASLD in the Fatty Liver Research Group of the Korean Diabetes Association.

Citations

Citations to this article as recorded by

Comparison of diagnostic criteria for fatty liver disease in assessing cardiac dysfunction: a cross-sectional study
Yun Kyung Cho, Myung Jin Kim, Eun Hee Kim, Min Jung Lee, Hyo-Jung Nam, Woo Je Lee, Hong-Kyu Kim, Chang Hee Jung
Hepatology International.2026; 20(1): 81. CrossRef
Biological determinants and outcomes of sex discrepancies in MASLD
Amedeo Lonardo, Mohamad Jamalinia, Ralf Weiskirchen
Metabolism and Target Organ Damage.2026;[Epub] CrossRef
Mazdutide Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Endoplasmic Reticulum Stress, Improving Lipid Metabolism and Alleviating Inflammation
Liangyu Gan, Lengxin Duan, Xueyi Zheng
Pharmaceuticals.2026; 19(3): 371. CrossRef
Special Population
Janus P. Ong, Hasmik Ghazinyan, Vincent Wai-Sun Wong, Yuichiro Eguchi
Clinics in Liver Disease.2026; 30(2): 435. CrossRef
Managing Metabolic Dysfunction–Associated Steatotic Liver Disease: Protocol for a Scoping Review of Patient Perceptions, Barriers, and Facilitators
Sikyeong Park, Yu Shin Park, Dahye Hong, Bada Kang
JMIR Research Protocols.2026; 15: e81404. CrossRef
Association between the Zhejiang University index and metabolic dysfunction-associated fatty liver disease as analyzed in National Health and Nutrition Examination Survey: A retrospective observational study
Wei Fu, Xiaoyue Wu, Guobin Cheng, Linya Lyu, Hulin Wang
Journal of International Medical Research.2026;[Epub] CrossRef
Aqueous Extract of Siraitia grosvenorii Alleviates MAFLD by Modulating Metabolism and Maintaining Gut Homeostasis in High-Fat Diet Fed Mice
Hong Li, Zhongzhen Zhao, Yiming Ding, Weixian Shao, Yu Zhou, Junxiu Li, Zailin Liang, Bin Peng, Fusheng Mo, Jiao Zheng, Shengli Wei, Yuan Zhang
Foods.2026; 15(7): 1241. CrossRef
Associations of body roundness index with steatotic liver disease and mortality from the UK biobank cohort study
Jinyoung Shin, Seok-Jae Heo, Yae-Ji Lee, Yu-Jin Kwon, Ji-Won Lee
BMC Gastroenterology.2026;[Epub] CrossRef
Income Persistence and the Risk of Hepatocellular Carcinoma in Individuals with Type 2 Diabetes
Jong-Ha Baek, Yong-Moon Mark Park, Benjamin C. Amick, Mario Schootman, Michael R. Thomsen, Oak-Kee Hong, Seung-Hyun Ko, Clare C. Brown, Marie-Rachelle Narcisse, Pearl A. McElfish, Seong-Su Lee, Kyungdo Han
Cancer Epidemiology, Biomarkers & Prevention.2026; 35(5): 743. CrossRef
Current Trends and Perspectives on Obesity and Metabolic Dysfunction-Associated Steatohepatitis in East Asia
Soo Lim, Hui Zhou, Wataru Ogawa
Journal of Obesity & Metabolic Syndrome.2026; 35(2): 130. CrossRef
DN203316, a novel PPARδ agonist, suppresses ferroptotic signaling and fibrogenesis in metabolic dysfunction-associated steatohepatitis
Ye Jin Kim, Jina Kim, Da Young An, Mihyang Park, Gui-Hwa Jeong, Jonghwa Jin, Mi Kyung Kim, Jungwook Chin, Yeon-Kyung Choi, Keun-Gyu Park
Experimental & Molecular Medicine.2026; 58(6): 1900. CrossRef
Association between the triglyceride-glycated hemoglobin index and diabetes risk among patients with Non-alcoholic fatty liver disease: A longitudinal cohort study
Cuimei Wei, Changchun Cao, Zengxin Xu, Gang Chen, Wenjing Liu, Miao Zhang, Haofei Hu, Shanghua Xu, Aleksandra Klisic
PLOS One.2026; 21(6): e0350633. CrossRef
Bioelectrical impedance analysis parameters are superior to liver enzymes in predicting metabolic dysfunction-associated steatotic liver disease in young adults
Kyungchul Song, Yu-Jin Kwon, Eunju Lee, Hye Sun Lee, Young Hoon Youn, Su Jung Baik, Hana Lee, Joon Young Kim, Youngha Choi, Hyun Wook Chae
Internal and Emergency Medicine.2025; 20(3): 785. CrossRef
Extracellular Vesicle-Mediated Network in the Pathogenesis of Obesity, Diabetes, Steatotic Liver Disease, and Cardiovascular Disease
Joonyub Lee, Won Gun Choi, Marie Rhee, Seung-Hwan Lee
Diabetes & Metabolism Journal.2025; 49(3): 348. CrossRef
SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application
Jae Hyun Bae
Diabetes & Metabolism Journal.2025; 49(3): 386. CrossRef
Association of temporal MASLD with type 2 diabetes, cardiovascular disease and mortality
Eugene Han, Kyung-Do Han, Yong-ho Lee, Kyung-Soo Kim, Sangmo Hong, Jung Hwan Park, Cheol-Young Park
Cardiovascular Diabetology.2025;[Epub] CrossRef
Development of a simple metabolic score to predict liver fibrosis risk in chronic hepatitis B patients: A retrospective cross-sectional study
Li Liu, Peng Ye, Qiuping Gu, Ling Zeng, Lijuan Liang, Yingfeng Wei
Journal of International Medical Research.2025;[Epub] CrossRef
2025 Clinical Practice Guidelines for Diabetes: Management of Metabolic Dysfunction-Associated Steatotic Liver Disease
Jaehyun Bae
The Journal of Korean Diabetes.2025; 26(3): 172. CrossRef
Research trends on the quality of life in patients with metabolic dysfunction-associated fatty liver diseases: a scientific metrology study
Can Huang, Meng Chen, Yanfang Sun, Lin Zhang, Wei Liu
Frontiers in Nutrition.2025;[Epub] CrossRef

First
Prev
Page of 1
Next
Last

Search